Document is current
Any future updates will be listed below
-
Authors
Rosenson, Robert S. https://orcid.org/0000-0002-5599-0633
Goonewardena, Sascha N. https://orcid.org/0000-0002-3772-8818
- License Information
-
More Information
Article History
First Online: 3 March 2026
Competing interests
: R.S.R. reports research funding to his institution from Amgen, Arrowhead, Lilly, Merck, NIH, Novartis, Novo Nordisk and 89Bio; consulting fees from Amgen, Arrowhead, Lilly, Intercept Pharmaceuticals, Life Extension, Lipigon, Novartis, Regeneron Pharmaceuticals, Inc., Rona Therapeutics and Verve Therapeutics; nonpromotional honoraria from TD Cowen and Viatris; royalties from Wolters Kluwer (UpToDate); stock holdings in MediMergent, LLC; and patent applications on Methods and Systems for Biocellular Marker Detection and Diagnosis using a Microfluidic Profiling Device (EFS ID: 32278349, application no. PCT/US2019/026364 (provisional)), and Compositions and Methods Relating to the Identification and Treatment of Immunothrombotic Conditions (New International application no. PCT/US2021/63104926). S.N.G. declares no competing interests.
